retatrutide phase 2 study results just delivered one of the largest weight-loss signals we've ever seen in a medication trial. In a study: • Up to 24.2% mean weight loss at 48 weeks Retatrutide just delivered the first

A role for glucagon-like peptide-1 in the central regulation of feeding

It was not the largest result, but it was far from a consolation prize

Awareness of these diverse techniques allows patients to make educated choices regarding their care and work towards the best possible outcome for their weight and appearance goals

All products sold by Beyond Health Lab are intended strictly for in vitro research and laboratory use only

Time-restricted eating (limiting food intake to an 8-12 hour window) has shown some metabolic benefits in small studies, but mechanisms are not fully established and may involve multiple hormonal pathways

While GLP-1 medications may reduce appetite and caloric intake, they can also lead to a reduction in overall protein consumption, which is vital for muscle maintenance and growth